PA PATH UiPath Inc. Loading... : Bullish and Bearish Analyst Opinions

UiPath’s management acknowledged that current per‑platform unit pricing slows adoption; they plan to transition to AI credits / outcome‑based pricing (Q4 FY26 earnings). A licensing shift would remove a key friction point, enabling faster upselling to Fortune 500 clients and boosting consumption‑based revenue, potentially accelerating RPO and NDR growth. If UiPath successfully flattens revenue lumpiness with standardized vertical “AI Playbooks” and more flexible pricing, the stock could re‑rate higher as the market recognizes a sustainable growth trajectory. Execution risk on pricing transition; competition from larger AI platform players; DoD deals may be lumpy; top comment indicates bag‑holders wanting to exit, suggesting weak near‑term momentum.

The tweet suggests a playful rename for UiPath to AIPath, but lacks any explicit position or forward-looking trade call.

UiPath Q1 earnings released; no directional view stated by speaker.

UiPath reports first quarter fiscal 2026 earnings with revenue up 17 percent year-over-year and ARR reaching 1.901 billion dollars.

PATH holds $1.5B cash, trades at ~4x last year’s revenue, and just posted its first positive EPS; 30% of float is short. The combination of undervaluation, accelerating enterprise AI adoption, and high short interest creates a squeeze/rerating opportunity. Buy calls (Jan ’27 $15c) to play medium-term growth and potential gamma/squeeze on earnings. Earnings miss, competition from other automation/AI integration platforms, macro-driven tech selloff, or failure to convert growth into sustained profitability.

The author argues UiPath is significantly undervalued due to its large cash balance, presenting a clear long opportunity.

The author recommends buying PATH as it is trading at a 40% discount, implying significant upside.

Heavily corrected stocks are showing resilience and reduced selling pressure during broader market weakness.

The tweet highlights significant year-to-date losses for five stocks, casting doubt on their current valuation.

UiPath shares are experiencing a significant decline of over 9% today.

Companies that use AI to automate tasks for the better — service-based ideas; $PATH listed as one to invest in.

The author suggests that even with decent earnings, the fundamental long-term bull case for the stock is weak, implying it is not a buy and is likely to underperform.

"UiPath, a software company... down by 5%... back to some growth prospect concerns by Bloomberg Intelligence." In a macro environment plagued by high rates and geopolitical uncertainty, enterprise software companies with decelerating growth are heavily penalized. As corporations scrutinize IT budgets and shift spending toward pure-play generative AI, legacy automation software names will suffer severe multiple compression. SHORT. Weakening growth prospects in a risk-off macro environment make mid-tier software highly vulnerable. A broader tech sector rally, a surprise earnings beat, or an acquisition offer could force a rapid short squeeze.

The company is providing strong forward guidance for significant revenue growth and margin expansion, driven by the secular trend of AI adoption.

UiPath reports solid year-over-year growth in revenue and ARR alongside strong gross margins.

"UI path, some others that have maybe more one trick pony business models that could be disintermediate." Unlike Salesforce or Microsoft (which own the data), UiPath focuses on task automation (RPA). Ives implies that Generative AI agents can inherently perform these tasks without needing specialized RPA software, making their business model existentialy vulnerable. AVOID (or SHORT). Differentiate them from the "winners" in the software stack. UiPath successfully pivots to becoming an AI-agent orchestrator, proving the bear case wrong.

Barkin attributes the impressive 2.8% productivity number to companies that "invested in new processes, new staffing models, automation" and "AI" because they were caught short of workers three years ago. The "Productivity" Barkin praises is not magic; it is Capex spending. Companies are buying hardware (Rockwell), software (Microsoft), and automation tools (UiPath) to protect margins. If the Fed sees this as the solution to inflation, corporate spend will continue to funnel here. LONG. This is a structural play on the "Margin Protection" trade. Tech valuation compression if interest rates spike due to the oil shock.

UiPath (Robotic Process Automation). The stock is too expensive, and the thesis that bots will replace mundane tasks is not compelling enough to justify the valuation.

Speaker references $ZETA and $PATH as past trend picks by another user, no directional view or position stated.